By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cellectar Biosciences (Formerly Known As Novelos Therapeutics, Inc.)  

3301 Agriculture Drive

Madison  Wisconsin  53716  U.S.A.
Phone: 608-441-8120 Fax: 608-441-8120


Key Statistics

Ownership: Public

Web Site: Cellectar Biosciences
Symbol: CLRB


Drug Discovery

Company News
Cellectar Biosciences  (CLRB) Presents Poster At The 58th Annual Meeting Of The American Society of Hematology 12/6/2016 7:42:42 AM
Cellectar Biosciences  (CLRB) Announces Results From The First Two Cohorts Of Its CLR 131 Phase I Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, And Progression Free Survival Similar To Or Better Than Recently Approved Therapies 12/1/2016 7:14:59 AM
Cellectar Biosciences  (CLRB) Announces Successful Completion Of $9.2 Million Public Offering, Which Includes Full Exercise Of $1.2 Million Over-Allotment Option 11/30/2016 8:10:52 AM
Cellectar Biosciences  (CLRB) Announces Partnership With Radiopharmaceutical Specialists, CPDC, To Establish Manufacturing Capacity In Anticipation Of CLR 131 Pivotal Trial And Commercial Production 11/28/2016 7:16:06 AM
Cellectar Biosciences  (CLRB) Announces Pricing Of $8,000,000 Public Offering 11/23/2016 7:13:07 AM
Cellectar Biosciences  (CLRB) Announces Successful Conjugation Of Multiple Pierre Fabre Cytotoxic Compounds To PDC Delivery Platform; Initiates In Vivo Studies For Solid Tumors 11/17/2016 7:37:00 AM
Cellectar Biosciences  (CLRB) Announces INC Research (INCR) As The CRO For The Phase II Trial Of CLR 131 In Hematologic Malignancies; $2 Million NCI Grant Covers Half Of Study Cost, With Potential Option To Pursue Additional $3 Million For Pivotal Trial 11/15/2016 8:34:35 AM
Cellectar Biosciences  (CLRB) Announces Recent Key Accomplishments And Third Quarter 2016 Financial Results 11/11/2016 9:19:24 AM
Cellectar Biosciences  (CLRB) To Host Conference Call On November 11 To Report Third Quarter 2016 Financial Results And Corporate Performance 11/7/2016 8:04:38 AM
Cellectar Biosciences  (CLRB) Announces Design For NCI-Supported Phase II Study Of CLR 131 In Multiple Myeloma And Other Hematologic Malignancies 10/31/2016 7:50:44 AM